This site is intended for healthcare professionals
Drug information

Griseofulvin 500mg Tablets

POM
Read time: 10 mins
Last updated: 23 Sep 2020
Published: 23 Sep 2020

4.1 Therapeutic indications

The treatment of fungal infections of the skin, scalp, hair, or nails (Tinea barbae, Tinea capitis, Tinea corporis, Tinea cruris, Tinea pedis, Tinea unguium) where topical therapy is considered inappropriate, or the infection has proven refractory to topical therapy.

Oral administration of griseofulvin for systemic therapy of fungal infections enables newly formed keratin of the skin, hair, and nails to resist fungal attack. As the new keratin extends, the old infected keratin is shed.

Prior to therapy, the type of fungi responsible should be identified. The use of griseofulvin is not justified in the treatment of minor or trivial infections that will respond to topical therapy.

Before prescribing Griseofulvin Tablets, consideration should be given to national and/or local guidance on the appropriate use of antifungals.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).